





TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER School of Medicine Cancer Center

## **Cell Line Data Sheet for Rh18**

Disease: Histology Subtype: Phase of Therapy: Treatment: Disease Stage: Gender: Age at diagnosis: Race: Age at sample collection: Source of Culture: Primary Tumor Site: Date Established:	Rhabdomyosarcoma Predominately Embryonal (Mixed Aveolar and Embryonal subtype) Diagnosis None 4 N/A 24 months N/A N/A Solid tumor from mouse xenograft Perineum			
PAX-FKHR Status: p53 functionality: Karyotype: Modal No:	Positive for translocation Non-Functional			
R-IC50 (DIMSCAN*): *see reference 1	Vincristine (ng/ml) 0.19 ± 0.28	<u>Melphalan (µg/ml)</u> 17.74 ± 1.38	Etoposide (ng/ml) 18.80 ± 2.27	<u>Rapamycin (ng/ml)</u> N/A
Growth Conditions:	Please see Protocols section at <u>https://www.cccells.org/protocols.php</u> 5% CO <sub>2</sub> , 20% O <sub>2</sub> , 37.0°C			
Media Formulation:	Please see Protocols section at <u>https://www.cccells.org/protocols.php</u> Cells are grown in a base medium of Iscove's Modified Dulbecco's Medium plus the following supplements (to a final concentration): 20% Fetal Bovine Serum, 4mM L-Glutamine, 1X ITS (5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenous acid)			
Doubling Time: Growth Properties:	65 hours Teardrop-shaped cells with processes, adherent			
STR Profile:	May be obtained at <u>https://strdb.cccells.org/</u>			
Notes:	Positive for MyoD1 and myogenin			

All COG Repository cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO. Each vial label contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen. All cell lines are validated with original patient sample by STR analysis.

Childhood Cancer Repository Powered by Alex's Lemonade Stand COG resource Laboratory www.cccells.org





TECH UNIVERSITY

HEALTH SCIENCES CENTER.

School of Medicine

Cancer Center


## **Cell Line Data Sheet for Rh18**

## **References:**

 Kang MH, Smith MA, Morton CL, Keshelava N, Houghton PJ, Reynolds CP. National Cancer Institute Pediatric Preclinical Testing Program: Model Description for In Vitro Cytotoxicity Testing. Pediatric Blood Cancer 56: 239-249, 2011. PubMed ID: 20922763 <u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005554/</u>

SEE NCI Pediatric Preclinical Testing Program references.

- Petak, I., Douglas, L., Tillman, D.M., Vernes, R., Houghton, J.A. (2000). Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis. Clin Cancer Res 6, 4119-27. PM:11051265 https://clincancerres.aacrjournals.org/content/6/10/4119.long
- Hazelton, B.J., Houghton, J.A., Parham, D.M., Douglass, E.C., Torrance, P.M., Holt, H., Houghton, P.J. (1987). Characterization of Cell Lines Derived from Xenografts of Childhood Rhabdomyosarcoma. Cancer Res 47, 4501-7. PMID: 3607778 <u>https://cancerres.aacrjournals.org/content/47/16/4501.long</u>



COG resource Laboratory

TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER. 3/3

TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER.

TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER. School of Medicine